Impact of preoperative anemia on relapse and survival in breast cancer patients

Zhang, Ying Jun; Chen, Yu Yang; Chen, Dong Tai; Jiang, Yu; Huang, Wan; Ouyang, Han Dong; Xing, Wei; Zeng, Mu Sheng; Xie, Xiao; Zeng, Weian

doi:10.1186/1471-2407-14-844

Cited by 47 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study evaluated the outcome of 367 patients with soft tissue sarcoma and found that low preoperative hemoglobin levels were significantly associated with decreased cancer‐specific survival and OS . Studies from our center have reported that preoperative anemia was an independent predictor of outcome in breast cancer . It should be noted that one similar sized study from Korea showed that preoperative anemia was an independent prognostic factor for TNM stage I‐II GC but not stage III .…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients

et al. 2018

View full text Add to dashboard Cite

We sought to evaluate whether preoperative anemia was an important determinant of survival in gastric cancer (GC). A single institution cohort of 2163 GC patients who underwent curative resection were retrospectively analyzed. Anemia was defined as a preoperative hemoglobin level <120 g/L in males and <110 g/L in females. Overall survival (OS) was analyzed using the Kaplan–Meier method, and a multivariate Cox proportional hazards model was performed to identify the independent prognostic factor. Anemic patients had a poorer OS compared with nonanemic patients after resection for tumor–nodes–metastasis (TNM) stage III tumors (5‐year OS rate: 32.2% vs. 45.7%, P < 0.001) but not stage I (P = 0.480) or stage II (P = 0.917) tumors. Multivariate analysis revealed that preoperative anemia was an independent prognostic factor in TNM stage III (hazard ratio [HR], 1.771; 95% CI, 1.040–3.015; P = 0.035). In a stage‐stratified analysis, preoperative anemia was still independently associated with OS in TNM stages IIIa through IIIc (P < 0.001, P = 0.075, and P = 0.012, respectively), though the association was only marginal in stage IIIb. Of note, preoperative mild anemia had a similar prognostic value in TNM stage III GC. Furthermore, preoperative anemia was significantly associated with more perioperative transfusions, postoperative complications and several nutritional‐based indices, including the prognostic nutritional index (PNI), preoperative weight loss and performance status (all P < 0.05). Preoperative anemia, even mild anemia, was an important predictor of postoperative survival for TNM stage III GC.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Furthermore, a study from Zhang et al. also revealed that preoperative anemia was significantly correlated with preoperative nutritional status . In fact, accumulating evidence has indicated that preoperative malnutrition induces poor clinical outcomes .…”

Section: Discussionmentioning

confidence: 97%

Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In this study, low hemoglobin levels at baseline were associated with reduced TTF. Moreover, previous studies associated the low hemoglobin levels including anemia with poor survival prognosis in breast cancer patients [25][26][27][28]. Thus, low hemoglobin levels may be a robust prognostic indicator for reduced TTF for breast cancer patients.…”

Section: Discussionmentioning

confidence: 98%

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

et al. 2020

View full text Add to dashboard Cite

Background Data on eribulin as the first-or second-line treatment in a clinical setting, especially the overall survival (OS) of patients, are scarce. Therefore, we assessed the effectiveness and safety of eribulin as the first-, second-, and third-or later-line treatments in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in Japan. Methods This multicenter, prospective, post-marketing, observational study enrolled patients from September 2014 to February 2016 in Japan and followed them for 2 years. Patients were categorized by eribulin use into the first-, second-, and third-or later-line treatment groups. Results Of 651 registered patients, 637 patients were included in the safety and effectiveness analysis. In all, first-, second-, and third or later-line treatment groups, median OS (95% confidence interval) were 15.6 (13.8-17.6), 22.8 (17.3-31.0), 16.3 (12.4-19.9), and 12.6 (11.2-15.1) months and time to treatment failure (TTF) (95% confidence interval) were 4.2 (3.7-4.4), 5.2 (3.7-5.9), 4.2 (3.7-5.1), and 3.8 (3.5-4.2) months, respectively. Prolonged TTF was associated with complications of diabetes and the development of peripheral neuropathy after eribulin treatment, according to multivariate Cox regression analysis. Grade ≥ 3 adverse drug reactions (ADRs) were reported in 61.7% of the patients. Neutropenia (49.5%) was the most common grade ≥ 3 ADR in all groups. Conclusions The effectiveness and safety results of eribulin as the first-or second-line treatment were favorable. Thus, these suggest eribulin may be a first-line treatment candidate for patients with HER2-negative advanced breast cancer in Japan.

show abstract

“…The HCT test is often used to check for anemia, usually along with a hemoglobin test or as part of a complete blood count[27]. In previous studies, pretreatment anemia, indicated by low Hb levels, was reported to negatively influence cancer patients’ clinical outcome[28,29], including breast cancer[15]. However, little is known about the prognostic value of HCT in TNBC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a research indicates that anemia pretreatment in breast cancer patients might deteriorate the pathological response to neoadjuvant chemotherapy as well as survival status[14]. Moreover, in breast cancer, anemic patients (Hb< 12.0 g/dl) had a worse local relapse-free survival (LRFS), relapse-free survival (RFS), and overall survival (OS) than those without anemia (Hb≥12.0 g/dl), even exclude the influence of clinical stage[15]. …”

Section: Introductionmentioning

confidence: 99%

Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundAnemia usually refers to low hemoglobin (Hb) levels. Previous studies indicated that anemia negatively influence the survival in various cancers. Hematocrit (HCT) is the volume percentage of red blood cells in blood, which could indicate anemia in both individuals and populations. This study compared the value of HCT with that of Hb for predicting outcomes of patients who underwent treatment for triple negative breast cancer (TNBC).MethodsA retrospective study of 293 triple negative breast cancer patients, accepting treatment from January 2004 to December 2009 at Sun Yat-sen University Cancer Center, was conducted. Kaplan-Meier curves and multivariate Cox proportional models were used to calculate disease free survival (DFS) and overall survival (OS).ResultsThe cut-off value of HCT was 35.9% determined by X-tile software analysis. The cut-off value of Hb was 12.0 g/dl based on the World Health Organization (WHO) criteria. In univariate analysis, low HCT and low Hb were both significantly associated with decreased DFS and OS. In multivariate analysis, HCT (HR: 0.570; 95% CI: 0.331–0.981, P = 0.042 for DFS; HR: 0.456; 95% CI: 0.256–0.813, P = 0.008 for OS) was still identified as independent predictor of outcome, but not Hb.ConclusionPretreatment low HCT is independently associated with poor prognosis in TNBC patients. However, HCT was found to be superior to Hb in terms of predicting breast cancer mortality. In the future, large-scale prospective studies or validation studies are needed to verify our findings.

show abstract

Impact of preoperative anemia on relapse and survival in breast cancer patients

Cited by 47 publications

References 40 publications

Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients

Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer

Contact Info

Product

Resources

About